Get the Stockscreener App
186.36
5.36%
-10.55
After Hours:
194.00
7.64
+4.10%
Natera Inc stock is traded at $186.36, with a volume of 2.23M.
It is down -5.36% in the last 24 hours and down -10.05% over the past month.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
See More
Previous Close:
$196.91
Open:
$197.61
24h Volume:
2.23M
Relative Volume:
1.68
Market Cap:
$26.69B
Revenue:
$2.50B
Net Income/Loss:
$-226.32M
P/E Ratio:
-113.55
EPS:
-1.6412
Net Cash Flow:
$71.51M
1W Performance:
-4.06%
1M Performance:
-10.05%
6M Performance:
-8.77%
1Y Performance:
+24.74%
1-Day Range:
$184.81
$198.65
1-Week Range:
$184.81
$206.00
52-Week Range:
$131.81
$256.36
Natera Inc Stock (NTRA) Company Profile
Name
Natera Inc
Sector
Industry
Phone
650-249-9090
Address
13011 MCCALLEN PASS, AUSTIN, CA
Compare NTRA vs TMO, DHR, IDXX, WAT, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NTRA
Natera Inc
|
186.36 | 28.20B | 2.50B | -226.32M | 71.51M | -1.6412 |
TMO
Thermo Fisher Scientific Inc
|
438.34 | 166.56B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
161.91 | 116.46B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
528.79 | 42.03B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
329.22 | 32.72B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
111.70 | 32.01B | 7.07B | 1.29B | 993.00M | 4.5355 |
Natera Inc Stock (NTRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-14-26 | Initiated | William Blair | Outperform |
| Jan-07-26 | Initiated | Citigroup | Buy |
| Dec-02-25 | Resumed | Morgan Stanley | Overweight |
| Oct-27-25 | Upgrade | BNP Paribas Exane | Underperform → Neutral |
| Sep-22-25 | Resumed | Wells Fargo | Equal Weight |
| Mar-13-25 | Initiated | RBC Capital Mkts | Outperform |
| Jan-23-25 | Initiated | Barclays | Overweight |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-08-24 | Resumed | Craig Hallum | Buy |
| Feb-20-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-29-23 | Reiterated | BTIG Research | Buy |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Nov-13-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-28-23 | Initiated | Bernstein | Mkt Perform |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-05-23 | Initiated | UBS | Buy |
| Jan-18-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Apr-25-22 | Initiated | Stephens | Overweight |
| Mar-08-22 | Initiated | Goldman | Buy |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| May-25-21 | Initiated | Wells Fargo | Overweight |
| Jan-28-21 | Initiated | Truist | Buy |
| Oct-08-20 | Initiated | BTIG Research | Buy |
| Sep-28-20 | Initiated | Morgan Stanley | Overweight |
| Sep-17-20 | Initiated | SVB Leerink | Outperform |
| Jun-10-20 | Resumed | Piper Sandler | Overweight |
| May-07-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-05-18 | Initiated | JP Morgan | Neutral |
| Jul-05-18 | Reiterated | Piper Jaffray | Overweight |
| Aug-07-17 | Reiterated | Morgan Stanley | Overweight |
| Nov-10-16 | Reiterated | The Benchmark Company | Buy |
| May-23-16 | Reiterated | The Benchmark Company | Buy |
| May-11-16 | Reiterated | The Benchmark Company | Buy |
| Apr-19-16 | Initiated | The Benchmark Company | Buy |
| Sep-28-15 | Upgrade | Wedbush | Neutral → Outperform |
| Aug-14-15 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-04-15 | Initiated | Robert W. Baird | Outperform |
| Jul-27-15 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-27-15 | Initiated | Piper Jaffray | Overweight |
| Jul-27-15 | Initiated | Wedbush | Neutral |
View All
Natera Inc Stock (NTRA) Latest News
Natera Inc stock (US6323071042): insider selling and a sharp pullback unsettle investors - AD HOC NEWS
Natera Scores Rare FDA Approval but Shares Drop - TechStock²
Natera co-founder Sheena Jonathan sells $959,450 in company stock - Investing.com
Natera (NTRA) co-founder Jonathan Sheena sells 4,650 shares under 10b5-1 plans - Stock Titan
New blood test helps tailor bladder cancer treatment, wins FDA backing - Stock Titan
Roche's ctDNA-guided approach in post-surgical bladder cancer pays off with Tecentriq nod - Fierce Pharma
Natera's Signatera CDx Approved by FDA as Companion Diagnostic in Muscle-Invasive Bladder Cancer - Moomoo
Natera Gets FDA Approval for Bladder-Cancer Test - marketscreener.com
Signatera CDx Approved by the FDA as a Companion Diagnostic in Muscle-Invasive Bladder Cancer (MIBC) - Business Wire
NTRA Technical Analysis | Trend, Signals & Chart Patterns | NATERA INC (NASDAQ:NTRA) - ChartMill
Natera’s Stronghold in Cancer Recurrence Tests Prompts Wood’s Ark to Expand Stake - The Daily Upside
(NTRA) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Natera, Inc.Common Stock (NQ: NTRA - FinancialContent
Natera NTRA Q1 2026 Earnings Call Transcript - AOL.com
The Cancer Test That Wall Street Is Betting On - Mint
5 Must-Read Analyst Questions From Natera’s Q1 Earnings Call - The Globe and Mail
Natera (NTRA) Sees Recent Investment Surge from ARK Investment - GuruFocus
Cathie Wood’s ARK sells Twist Bioscience, buys Natera stock - Investing.com
Cathie Wood’s ARK sells Twist Bioscience, buys Natera stock By Investing.com - Investing.com Australia
Analysts Have Made A Financial Statement On Natera, Inc.'s (NASDAQ:NTRA) First-Quarter Report - simplywall.st
Natera, Inc. (NASDAQ:NTRA) Just Released Its First-Quarter Earnings: Here's What Analysts Think - Moomoo
Why Natera (NTRA) Shares Are Plunging Today - Yahoo Finance
Natera price target raised to $249 from $240 at Piper Sandler - TipRanks
Why Natera (NTRA) Is Down 5.9% After Raising 2026 Guidance But Posting a Wider Q1 Loss - simplywall.st
NTRA Stock Price, Quote & Chart | NATERA INC (NASDAQ:NTRA) - ChartMill
NTRA Q1 Deep Dive: Robust Volume Growth and Product Expansion Shape Outlook - Yahoo Finance
Number of shareholders of Natera, Inc. – BX:NTRA - TradingView
Earnings call transcript: Natera Inc. sees mixed Q1 2026 results; stock drops By Investing.com - Investing.com Australia
NTRA Maintained by BTIG -- Price Target Lowered to $250 - GuruFocus
Earnings call transcript: Natera Inc. sees mixed Q1 2026 results; stock drops - Investing.com
Natera stock price target lowered to $250 by BTIG on valuation - Investing.com Nigeria
Assessing Natera (NTRA) Valuation After Recent Share Price Pullback And Long Term Returns - Yahoo Finance
Assessing Natera (NTRA) Valuation After Record Q1 Growth And Ongoing Profitability Concerns - simplywall.st
Natera (NTRA) Is Up 6.6% After Record Q1 Revenue But Wider LossesHas The Bull Case Changed? - Yahoo Finance
Natera Lifts 2026 Outlook As Test Volumes Climb And Japan Entry Nears - Sahm
Natera (NTRA) Q4 Profit Of US$47.3 Million Tests Longstanding Loss‑Making Narrative - Sahm
Natera Stock To $136? - Trefis
Natera Q1 2026 slides: revenue jumps 39%, guidance raised By Investing.com - Investing.com South Africa
Natera’s Earnings Call Signals Strong Growth Momentum - TipRanks
NTRA Maintained by JP Morgan -- Price Target Raised to $265 - GuruFocus
Natera Price Target Raised to $220.00/Share From $215.00 by Wells Fargo - Moomoo
Natera (NTRA) Eps Diluted (TTM) - Zacks Investment Research
NTRA Maintained by Evercore ISI Group -- Price Target Raised to $270 - GuruFocus
NTRA Maintained by Wells Fargo -- Price Target Raised to $220 - GuruFocus
Natera, Inc. Stock 12‑Month Price Target Raised to $260.78, Implies 19% Upside - TradingView
Natera Inc Stock (NTRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Natera Inc Stock (NTRA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Sheena Jonathan | CO-FOUNDER |
May 13 '26 |
Sale |
201.56 |
1,500 |
302,347 |
19,532 |
| Rabinowitz Matthew | EXECUTIVE CHAIRMAN |
May 05 '26 |
Sale |
213.77 |
6,986 |
1,493,363 |
2,376,402 |
| Rabinowitz Matthew | EXECUTIVE CHAIRMAN |
May 04 '26 |
Sale |
206.16 |
722 |
148,848 |
2,382,440 |
| Brophy Michael Burkes | CHIEF FINANCIAL OFFICER |
May 04 '26 |
Sale |
210.49 |
482 |
101,456 |
57,496 |
| Brophy Michael Burkes | CHIEF FINANCIAL OFFICER |
May 01 '26 |
Sale |
206.16 |
313 |
64,528 |
57,978 |
| Sheena Jonathan | CO-FOUNDER |
May 01 '26 |
Sale |
206.16 |
107 |
22,059 |
255,652 |
| Moshkevich Solomon | PRESIDENT, CLINICALDIAGNOSTICS |
May 01 '26 |
Sale |
203.69 |
3,405 |
693,560 |
142,295 |
| Fesko John | PRESIDENT, CHIEF BUS. OFFICER |
May 01 '26 |
Sale |
206.16 |
291 |
59,993 |
187,220 |
| Chapman Steven Leonard | CEO AND PRESIDENT |
May 01 '26 |
Sale |
206.16 |
902 |
185,956 |
149,867 |
| RABINOWITZ DANIEL | SEC. AND CHIEF LEGAL OFFICER |
May 01 '26 |
Sale |
206.16 |
330 |
68,033 |
222,694 |
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):